Safety and Efficacy of FIT039 for Verruca Vulgaris: A Placebo-Controlled, Phase I/II Randomized Controlled Trial
Trial design: Human papillomavirus infection causes verruca vulgaris. CDK9 inhibitor FIT039 inhibits DNA virus proliferation in animal models. We conducted a multicenter, single-blind, placebo-controlled, randomized phase I/II clinical trial evaluating the safety and efficacy of FIT039 against verru...
Gespeichert in:
Hauptverfasser: | , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Buch |
Veröffentlicht: |
Elsevier,
2021-09-01T00:00:00Z.
|
Schlagworte: | |
Online-Zugang: | Connect to this object online. |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Online
Connect to this object online.3rd Floor Main Library
Signatur: |
A1234.567 |
---|---|
Exemplar 1 | Verfügbar |